Onco Actu du 17 novembre 2016

	3.1 Tabac
Cuts to public health funding are crippling Stop Smoking Services [Cancer Research UK] Cutting funds to these services is a false economy; increasing the risk of more people developing cancer because of smoking, and leading to higher costs to the NHS for managing and treating these diseases in the long term.
	5. Traitements
Pop-up pill could stay in stomach to release drugs for days [STAT] The new device has so far only been tested on pigs, not humans, but results published Wednesday in Science Translational Medicine could pave the way for human trials next year.
Modified virus could turn immune system on liver cancer [Cancer Research UK] The researchers suggest that the virus’ double blow may be a more effective treatment than what is currently available for liver cancer.
Direct Small-Molecule Inhibitors of KRAS [ESMO] From undruggable target to drug discovery on horizon.
The Drug Development Paradigm in Oncology: A Workshop [National Academies] Workshop participants will discuss challenges with the traditional phased drug development paradigm in the age of targeted therapies, best practices for cancer drug development and review, lessons learned from recent expedited drug approval processes, and evidence requirements for cancer therapies before and after regulatory approval, as well as the mechanisms needed to generate this knowledge.
	5.12.1 Immunothérapies - partenariats
Merck pairs PD-1 powerhouse Keytruda with Genexine vax to fight HPV-based cancers [FiercePharma] Merck will test its cancer-fighting checkpoint inhibitor Keytruda in combo with the biotech’s cancer vaccine, GX-188E, in HPV-induced cancers. They’ll start with a Phase Ib/IIa trial, with an option to expand the collaboration into Phase III registration studies in the indication.
Bristol-Myers, Enterome pen microbiome I/O research pact [FierceBiotech] Coming on the heels of a separate pact with Johns Hopkins University, the deal marks the second time in a week Bristol-Myers has looked outside its walls for help understanding the effect of the microbiome on responses and resistance to immuno-oncology.
Bristol-Myers Squibb and Enterome Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive Molecules [BMS] Enterome was established in 2012 in Paris, France to develop the discoveries made by the INRA metagenomic platform.
	5.2 Pharma
Amgen, Allergan step up to challenge Roche's Avastin with FDA biosim filing [FiercePharma] If it successfully gets by regulators, the pair could get a shot at snagging a piece of Avastin’s CHF 6.68 billion ($6.66 billion) 2015 haul.
Led by Former Lilly Exec, Apexian Out to Tackle Pancreatic Cancer [Xconomy] The Apexian small-molecule drug works by binding to APE1/Ref-1, a dual protein key in the development and growth in tumors.
ARIAD Announces Data Presentations at the World Conference on Lung Cancer [Ariad] Investigational Medicine Brigatinib Demonstrates 53 Percent Confirmed Objective Response Rate and 15.6-Month Median Progression-Free Survival by Independent Review Committee Assessment in ALTA Study Abstract.
Bristol-Myers Squibb Presents New Data at IASLC 17th World Conference on Lung Cancer Underscoring Progress and Leadership in Broad Lung Development Program [BMS] CheckMate -012 data for Opdivo monotherapy and in combination with Yervoy in first-line treatment of advanced non-small cell lung cancer, to be presented.
Gilead racks up another R&D setback as myelofibrosis drug flounders in PhIII [EndPoints] The setback on momelotinib comes near the end of what has turned into a grim year for Gilead.
	5.2.3 Pharma - économie
How to Lower Drug Prices, Improve Care, and Save Pharma [Xconomy] The problem is not prices but productivity, or more precisely, lack of productivity. Prices are a secondary effect of the industry’s inability to develop new drugs in sufficient quantities to sustain a market, to say nothing of meeting the needs of patients.
	5.4 Traitements - Economie
NICE approves three quarters of CDF group 1 drugs for routine use [NICE] More than 75% of treatments in the Cancer Drugs Fund (CDF) which have been looked at again by NICE have received positive recommendations for routine NHS use.
The AMA on value-based drug pricing [Healthcare Economist] Not only are payers and policymakers getting on board with value-based drug pricing, but providers–like the American Medical Association–and even life sciences companies themselves are getting on board.
NICE says pancreatic cancer treatment considered not cost effective for routine NHS use [NICE] The NICE appraisal committee, looked at research showing patients taking the drug pegylated liposomal irinotecan lived on average two months longer than those receiving usual care, and said it did not offer value for money for widespread NHS use.
Breast cancer drug approved for NHS use after price cut [The Guardian] Perjeta, the brand name of pertuzumab, could be helpful in the treatment of 1,400 women a year who develop a particularly aggressive form of breast cancer, but it was initially turned down by Nice, the National Institute for Healthcare Excellence, because of the high price set by the manufacturer, Roche.
Japan sets 50 percent price cut for Bristol Myers' Opdivo cancer drug [Reuters] The halving of the price on Opdivo, approved in Japan for treating advanced melanoma, non-small cell lung cancer and kidney cancer, will take effect from February 1, 2017, Ono Pharmaceutical said in an emailed statement on Wednesday.
Roche, Bristol-Myers cut cancer drug prices to win UK approval [Reuters] Other international drugmakers including Novartis and Pfizer have also offered increased discounts in recent months. The exact size of all these discounts is commercially confidential.
America's drug problem [Nature Biotechnology] Chasing treatments and gouging patients in a bloated, capitalist healthcare system.
	5.5 ASCO
ASCO’s TAPUR Study Now Has More Than One Hundred Participants Receiving Treatment Drugs and Twenty-Five New Clinical Trial Sites [ASCO] In the eight months since the trial opened, 174 individuals have consented to participate, and 105 participants have begun receiving a TAPUR Study drug.
	6. Lutte contre les cancers
DIY breast reconstruction: Device lets women do part of the surgical prep at home [STAT] While biking home one day, Jacobs had an idea: Why couldn’t a tiny can of compressed gas, like the one he carries to fix a flat tire, be used to let women inflate their own tissue expanders, a little each day so there is less stretching at a time and less pain?
NHS England has at last listened to calls to focus on radiotherapy [The Telegraph] Radiotherapy has a much lower profile than its colleague, chemotherapy, yet it is acknowledged to be cost-effective and cutting-edge compared to other forms of treatment.
	6.1 Observation
Black African women almost twice as likely to be diagnosed with late stage breast cancer compared to white women [Cancer Research UK] Ethnicity and stage at diagnosis was collected for women diagnosed with breast cancer in England in 2012 and 2013.
	6.7 DMP, Big Data & applis
Neal Patterson’s Remarks from CHC [Cerner] “It was on New Year’s of last year when I got the phone call that I had cancer. I made a plan, got a strategy for treatment and then went to execute it. I realized God had a sense of humor: he put me in a place undergoing an EHR conversion.” “We’ve been through the digitization of health care. Now we’re going to make being a patient a new experience.”